What the safety record shows at a glance

Across every published knee-specific clinical study to date, no adverse events have been reported — neither in Schneider's 2016 prospective randomised study (n=13 in the ChondroFiller group) nor in Simeonov's 2024 independent case series of 17 patients followed over 12 months, and none flagged in the three-year post-market clinical follow-up (PMCF) data reviewed in the manufacturer's Clinical Evaluation Report (CER v09, April 2025).

The CER benchmarks this as a complication rate of approximately 0% — compared with up to 17% for ACI/MACI cellular therapies and 0–7% for microfracture. Reoperation rates of 3–8% sit well below the figures reported for those alternatives, which reach up to 37% for ACI/MACI and up to 41% for microfracture.

MRI evidence adds an objective layer to this picture. MOCART scores of 81.6–84.3 at 12 months confirm that the injectable collagen scaffold integrates progressively into surrounding native cartilage — greater than 80% defect filling with no tissue rejection signal detectable on imaging.

Taken together, the available data present a consistently favourable safety profile for this ultrasound-guided outpatient treatment pathway, though the picture should be read as a promising signal rather than a definitive all-clear.

Side effects documented in knee studies

Murine-derived collagen carries a theoretical risk of hypersensitivity — yet no allergic or immunogenic reaction has appeared in any published knee cohort. That absence from the clinical record is encouraging, but it reflects the scale of the available studies (n=13 in Schneider 2016, n=17 in Simeonov 2024) rather than systematic immunogenicity testing; this aspect of safety has not been formally evaluated at population scale.

For the days immediately following treatment, mild soreness and transient swelling are consistent with what any intra-articular knee procedure produces. Standard clinical practice includes intravenous antibiotic prophylaxis at the time of injection to address the baseline infection risk inherent to intra-articular placement.

One technique-specific risk is worth noting separately. Fibrous tissue formation has been documented where the collagen scaffold was overfilled — applied proud of the cartilage surface rather than flush with it. This finding comes from wrist data and has not been specifically reported in knee cohort publications, but it identifies precise application volume as a meaningful safety variable. Flush, level placement eliminates this outcome; excess volume introduces it.

The overall picture, then, is one of no recorded serious adverse events across the available follow-up periods — while recognising that the absence of events in small, predominantly single-centre studies is not the same assurance that large, independently powered trials with standardised adverse-event reporting would provide.

Technique-sensitive risks: overfilling and early loading

Both of the main modifiable safety considerations in this treatment pathway are knowable in advance — which makes them manageable through good clinical practice and clear patient guidance.

The first concerns application volume. Where the collagen scaffold is placed flush with the surrounding cartilage surface, repair tissue develops along the intended hyaline-like pathway. When the gel sits proud of that surface — even modestly overfilled — the regenerative response shifts towards fibrous tissue instead, producing a mechanically inferior repair with different surface geometry. Precise gel volume is therefore not a secondary technical detail: it is the primary clinician-controlled variable that determines tissue quality at the treated site.

The second variable is early mechanical loading. A 2024 in-vitro biomechanical study found that immediately after placement, ChondroFiller does not have sufficient stiffness to shield the opposing cartilage surface from load. This matters because the scaffold's cell-recruitment process — drawing the patient's own progenitor cells into the collagen matrix — takes time to establish, as confirmed by ex-vivo knee explant data showing meaningful cell migration by day 14. Loading the knee before that process is underway risks disrupting the scaffold before repair has meaningfully begun. Restricting weight-bearing in the first weeks after the injection is accordingly a safety-critical protocol element, not a general comfort precaution. Patients should receive clear, specific guidance from their treating clinician about when and how to resume normal activity progressively.

Who is and isn't suitable — patient selection as a safety boundary

The near-zero complication rate documented across published knee studies is not a property of the scaffold alone — it reflects a patient population selected for a specific type of defect. Understanding those selection criteria helps patients assess whether this pathway is likely to apply to them.

ChondroFiller is indicated for focal, contained chondral lesions graded III or IV on the ICRS scale, up to 6 cm² in area, with intact cartilage at the surrounding borders. 'Focal' is the operative word: a discrete, localised area of full- or near-full-thickness damage, not the widespread, diffuse thinning that characterises advanced knee osteoarthritis. Those surrounding borders matter structurally — the healthy rim of native cartilage provides the boundary within which the gel-phase scaffold is retained and stabilised while cell recruitment takes place.

Advanced joint degeneration, equivalent to Kellgren-Lawrence grade IV in the knee, is associated with poor outcomes and represents a relative contraindication. Hip cohort data from ChondroFiller studies confirm this pattern explicitly: patients with Tönnis grade 2–3 disease fared poorly, establishing that the scaffold is not a rescue treatment for bone-on-bone joint wear.

Existing malalignment or ligament instability should also be assessed before treatment, as abnormal loading distribution can undermine any focal cartilage repair regardless of the scaffold used.

MRI review is central to the selection process — it allows characterisation of defect depth, size, subchondral bone integrity, and the condition of the surrounding cartilage that clinical examination alone cannot reliably determine. A consultant-led assessment is required to confirm whether a patient's defect genuinely meets these criteria.

How ChondroFiller's safety compares with other knee cartilage options

The complication and reoperation figures cited in the opening section of this article come from the manufacturer's CER v09 (April 2025), which benchmarks ChondroFiller against microfracture and ACI/MACI using published literature comparators rather than a direct head-to-head trial. Readers should interpret them accordingly — as contextual reference points, not proof of superiority.

What those comparisons do not capture is the difference in tissue type produced. Microfracture stimulates fibrocartilage — a mechanically weaker, collagen-II-poor substitute that tends to degrade under load over time. ChondroFiller, by recruiting the patient's own progenitor cells into its acellular collagen matrix, aims to support hyaline-like repair tissue more closely resembling native articular cartilage. Whether that translates to better long-term joint surface durability in the knee remains an open question pending larger, longer-term data.

Procedural burden also differs meaningfully. ACI and MACI require two separate surgical stages — an initial biopsy to harvest chondrocytes, laboratory culture, then reimplantation weeks later. ChondroFiller is administered as a single outpatient injection appointment. Microfracture is a single-stage surgical procedure performed arthroscopically under anaesthesia. For patients weighing options, the procedural profile of each route is a practical consideration alongside the safety numbers.

Evidence gaps and what remains uncertain

All published knee-specific studies are small — 13 to 26 patients — and predominantly single-centre or conducted with manufacturer involvement. No independently powered RCT designed to detect adverse events using pre-specified definitions and independent adjudication has been published as of 2025.

Follow-up duration is a second constraint. The PMCF registry data extend to three years; beyond that window, the published record is silent. Whether repair tissue remains structurally intact and whether any late-onset complications emerge are, at present, unknown.

Systematic immunogenicity data are absent from the published record — a gap already noted in the side-effects section, but worth naming here as a specific missing dataset rather than a passing caveat.

Post-procedure weight-bearing protocols vary across the literature, and whether clinical sites apply a consistent, standardised approach is unclear from published reports. Given that early mechanical instability is a known property of the gel phase immediately after placement, this is a clinically relevant gap rather than a minor procedural detail.

The ultrasound-guided outpatient injection pathway used in current practice is also newer than the arthroscopic delivery studied in published trials; its specific safety profile in the knee has minimal independent peer-reviewed data of its own.

Every study completed to date has reported no adverse events within the available follow-up window. The single most important outstanding question is whether that record holds when the outpatient injection delivery route is studied with the same rigour as the arthroscopic trial setting.

1. [1] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid (cell free 2-component collagen gel) with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z